Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients

The document reviewed the potential use of antiandrogens as therapeutic agents in COVID-19 patients, focusing on their ability to regulate TMPRSS2 and ACE2, which are crucial for SARS-CoV-2 cell entry. Despite initial hypotheses and observational studies suggesting that androgen deprivation therapy (ADT) might reduce COVID-19 severity, clinical trials, including a population-based study with 4,532 participants, found no significant evidence that antiandrogen therapy improved COVID-19 outcomes. The research highlighted the complexity of androgen interactions in COVID-19 and concluded that while antiandrogens might influence viral entry mechanisms, they did not translate into improved clinical outcomes, indicating a need for further research.